help button home button Endocrine Society Endocrinology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Graziani, G.
Right arrow Articles by Navarra, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Graziani, G.
Right arrow Articles by Navarra, P.
Endocrinology Vol. 143, No. 3 807-813
Copyright © 2002 by The Endocrine Society


CRH-ACTH-POMC-ADRENAL

CRH Inhibits Cell Growth of Human Endometrial Adenocarcinoma Cells via CRH-Receptor 1-Mediated Activation of cAMP-PKA Pathway

Grazia Graziani, Lucio Tentori, Ilaria Portarena, Marcella Barbarino, Giuseppe Tringali, Giacomo Pozzoli and Pierluigi Navarra

Institute of Pharmacology, Catholic University Medical School (G.T., G.P., M.B., P.N.), Rome 00168, Italy; Pharmacology and Medical Oncology Section, Department of Neuroscience, University of Rome "Tor Vergata" (G.G., L.T., I.P.), Rome 00133, Italy

Address all correspondence and requests for reprints to: Prof. Pierluigi Navarra, Institute of Pharmacology, Catholic University Medical School, Largo Francesco Vito 1-00168 Rome, Italy. E-mail: . pnavarra{at}rm.unicatt.it

CRH produced by human endometrial cells exerts decidualizing activity via an autocrine mechanism mediated via CRH-R1 receptors. We postulated that such activity exerted by CRH on normal endometrial cells might translate into an antiproliferative action on endometrial-derived malignancies, provided that neoplastic cells maintain the expression of CRH receptors. In this light, here we investigated the possible antiproliferative effects of CRH in an adenocarcinoma cell line derived from human endometrium.

CRH induces time- and concentration-dependent inhibition of Ishikawa cell growth, the maximal effect (50% inhibition) being achieved after 3 d of treatment with 10-7 M CRH. A decrease in telomerase activity, which paralleled tumor growth inhibition, was also observed in CRH-treated samples. The antiproliferative effect was confirmed by colony-formation assay for long-term survival. This effect was counteracted in a concentration-dependent manner by both {alpha}-helical CRH and astressin; the former also showed intrinsic inhibitory activity. These findings suggested the involvement of CRH-R1 receptor subtype; this hypothesis was confirmed by RNase protection analysis showing the expression of human CRH-R1 mRNA. Experiments with the PKA inhibitor 14–22 amide and forskolin, as well as the measurement of intracellular cAMP, suggested the downstream involvement of cAMP-PKA pathway in CRH-induced inhibition of Ishikawa cell growth.




This article has been cited by other articles:


Home page
Proc. Natl. Acad. Sci. USAHome page
Z. Hao, Y. Huang, J. Cleman, I. S. Jovin, W. W. Vale, T. L. Bale, and F. J. Giordano
Urocortin2 inhibits tumor growth via effects on vascularization and cell proliferation
PNAS, March 11, 2008; 105(10): 3939 - 3944.
[Abstract] [Full Text] [PDF]


Home page
Obstet GynecolHome page
P. Florio, F. M. Reis, P. B. Torres, F. Calonaci, P. Toti, C. Bocchi, E. A. Linton, and F. Petraglia
Plasma Urocortin Levels in the Diagnosis of Ovarian Endometriosis
Obstet. Gynecol., September 1, 2007; 110(3): 594 - 600.
[Abstract] [Full Text] [PDF]


Home page
J EndocrinolHome page
P. Florio, G. De Falco, E. Leucci, M. Torricelli, P. B Torres, P. Toti, A. Dell'Anna, E. Tiso, R. Santopietro, L. Leoncini, et al.
Urocortin expression is downregulated in human endometrial carcinoma.
J. Endocrinol., July 1, 2006; 190(1): 99 - 105.
[Abstract] [Full Text] [PDF]


Home page
Endocr. Rev.Home page
E. W. Hillhouse and D. K. Grammatopoulos
The Molecular Mechanisms Underlying the Regulation of the Biological Activity of Corticotropin-Releasing Hormone Receptors: Implications for Physiology and Pathophysiology
Endocr. Rev., May 1, 2006; 27(3): 260 - 286.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
J. Cao, C. L. Cetrulo, and T. C. Theoharides
Corticotropin-Releasing Hormone Induces Vascular Endothelial Growth Factor Release from Human Mast Cells via the cAMP/Protein Kinase A/p38 Mitogen-Activated Protein Kinase Pathway
Mol. Pharmacol., March 1, 2006; 69(3): 998 - 1006.
[Abstract] [Full Text] [PDF]


Home page
Mol. Endocrinol.Home page
N. Papadopoulou, J. Chen, H. S. Randeva, M. A. Levine, E. W. Hillhouse, and D. K. Grammatopoulos
Protein Kinase A-Induced Negative Regulation of the Corticotropin-Releasing Hormone R1{alpha} Receptor-Extracellularly Regulated Kinase Signal Transduction Pathway: The Critical Role of Ser301 for Signaling Switch and Selectivity
Mol. Endocrinol., March 1, 2004; 18(3): 624 - 639.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
J. C. Reubi, B. Waser, W. Vale, and J. Rivier
Expression of CRF1 and CRF2 Receptors in Human Cancers
J. Clin. Endocrinol. Metab., July 1, 2003; 88(7): 3312 - 3320.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
G. Graziani, L. Tentori, I. Portarena, M. Vergati, and P. Navarra
Valproic Acid Increases the Stimulatory Effect of Estrogens on Proliferation of Human Endometrial Adenocarcinoma Cells
Endocrinology, July 1, 2003; 144(7): 2822 - 2828.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2002 by The Endocrine Society